aclidinium vs dupilumab
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aclidinium and dupilumab. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Dupixent
No summary available.
Dupixent is a medicine that can help treat several conditions. It works by blocking certain proteins in your body that cause inflammation.
Information not available.
Dupixent can treat moderate-to-severe atopic dermatitis (eczema) in adults and children 6 months and older. It is also used for asthma in people 6 years and older, especially if they have an eosinophilic phenotype or need oral steroids. Dupixent can also treat chronic rhinosinusitis with nasal polyps in adults and children 12 years and older, eosinophilic esophagitis in adults and children 1 year and older, prurigo nodularis and chronic spontaneous urticaria in adults and children 12 years and older, chronic obstructive pulmonary disease in adults, and bullous pemphigoid in adults.
Information not available.
Dupixent is a type of medicine called a monoclonal antibody. It blocks two proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13). By blocking these proteins, Dupixent helps to reduce inflammation and improve your symptoms.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Injection site reactions (like redness, swelling, or pain)
- • Conjunctivitis (pink eye)
- • Blepharitis (eyelid inflammation)
- • Oral herpes (cold sores)
- • Keratitis (inflammation of the cornea)
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Pruritus 48,441
- Dermatitis Atopic 37,675
- Rash 33,431
- Injection Site Pain 30,477
- Eczema 22,304
No specific warnings noted.
Dupixent can cause serious allergic reactions, including anaphylaxis. Stop using Dupixent and get medical help right away if you have any signs of an allergic reaction. Tell your doctor if you get new or worsening eye problems, such as conjunctivitis or keratitis. Dupixent can sometimes cause eosinophilic conditions, so watch for symptoms like a vasculitic rash, worsening lung symptoms, heart problems, kidney problems, or nerve damage. Do not stop taking steroid medicines suddenly when you start Dupixent. Talk to your doctor about how to slowly lower your steroid dose if needed. Tell your doctor if you develop new psoriasis symptoms or joint symptoms.
No pregnancy information available.
Tell your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry to track outcomes in women who use Dupixent during pregnancy; you can enroll by calling 1-877-311-8972. It is not known if Dupixent passes into breast milk or if it could harm a nursing baby, so talk to your doctor about the best way to feed your baby if you are using Dupixent.
Also Compare, Nearby Drugs
Compare aclidinium with
How to Read This aclidinium vs dupilumab Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while dupilumab sits within the Anti-IL-4/IL-13 Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while dupilumab has 172,328. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aclidinium or dupilumab.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.